# enVVeno Medical Corp

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/enVVeno Medical Corp).

## Overview

enVVeno Medical Corp is a U.S.-based medical device company focused on developing bioprosthetic venous valve technologies for severe chronic venous insufficiency. Its lead program, VenoValve, is a surgical replacement venous valve, and its second program, enVVe, is a transcatheter replacement venous valve under development for the deep veins of the leg.

## Products & services

• VenoValve surgical replacement venous valve
• enVVe transcatheter replacement venous valve
• Clinical development for deep venous disease
• Pre-clinical and pivotal study programs

- **VenoValve** (0%) — Surgical replacement venous valve designed to restore one-way blood flow in the deep veins of the leg.
- **enVVe** (0%) — Non-surgical, transcatheter-based replacement venous valve intended for deep venous insufficiency.
- **Clinical development services** (100%) — Research, testing, and clinical trial activities supporting product advancement and regulatory approval.

- VenoValve surgical replacement venous valve
- enVVe transcatheter replacement venous valve
- Clinical development for deep venous disease
- Pre-clinical and pivotal study programs

## Customers

The company’s end users are patients with severe chronic venous insufficiency, but the near-term economic customer is the healthcare system and the physicians who adopt the device after regulatory approval. Its products are intended for vascular surgeons, interventional specialists, and hospitals treating advanced venous disease. Because the company is still in development, commercial customers are not yet generating revenue.

- **Patients with severe chronic venous insufficiency** (primary) — They are the ultimate beneficiaries of VenoValve and enVVe, which are designed to improve venous blood flow and reduce symptoms of deep venous reflux.
- **Physicians and clinical investigators** (primary) — Vascular and interventional specialists evaluate, implant, and study the devices in clinical trials and will drive adoption after approval.
- **Hospitals and specialty treatment centers** (secondary) — These facilities would purchase and use the devices for procedural treatment of advanced venous disease once commercialized.

- Vascular surgeons treating severe chronic venous insufficiency
- Interventional physicians evaluating transcatheter venous repair
- Hospitals and specialty centers managing advanced venous disease
- Patients with deep venous reflux and venous ulcers
- Clinical investigators and trial sites supporting pivotal studies

## Geography

enVVeno Medical Corp is headquartered in the United States and conducts its development, regulatory, and clinical activities from the U.S. Its business is currently centered on U.S. FDA pathways, including pivotal study work and IDE-related preparation for its product candidates.

- Headquartered in the United States
- Clinical and regulatory work is centered on the U.S. FDA pathway
- VenoValve pivotal study is a U.S. program
- enVVe IDE filing and pivotal study planning are U.S.-focused
- No meaningful commercial geography yet because products are not approved

## Strategy

The company’s strategy is to advance VenoValve through the FDA appeal and regulatory pathway while continuing clinical development of enVVe. It is also building the evidence package needed to establish a new effectiveness pathway for replacement venous valves, since this category has limited precedent.

- **Secure regulatory pathway for VenoValve** (short-term) — Approval is the key gating item for first commercialization and for validating the category.
- **Advance enVVe into pivotal development** (medium-term) — A second product broadens the platform and reduces dependence on one device program.
- **Prepare for commercialization** (medium-term) — Commercial readiness is needed to convert clinical success into revenue after approval.

- Advance VenoValve through FDA review and appeal
- Build clinical evidence for a new venous valve regulatory pathway
- Prepare enVVe for IDE submission and pivotal testing
- Expand the product pipeline beyond the initial lead program
- Position for commercialization after regulatory clearance

## Risks

The company faces high regulatory risk because both products depend on FDA approval and, in VenoValve’s case, on acceptance of a novel effectiveness framework. It also faces development-stage financing risk, since it has no product revenue and must fund clinical trials, regulatory work, and commercialization preparation before any sales begin.

- **Regulatory approval risk** [critical] — The business depends on FDA clearance/approval for both product candidates, and VenoValve requires acceptance of a new effectiveness pathway.
- **Clinical development risk** [high] — Trial outcomes, safety endpoints, and pre-clinical results determine whether the programs can advance.
- **Financing and dilution risk** [high] — The company is pre-revenue and relies on external capital to fund R&D and commercialization preparation.
- **Commercial adoption risk** [medium] — Even after approval, physicians and hospitals must adopt a new device category with limited precedent.

- FDA approval risk for both VenoValve and enVVe
- Novel regulatory pathway risk for replacement venous valves
- Clinical trial risk if endpoints or safety data are insufficient
- Financing risk because the company has no product revenue
- Commercialization risk if adoption is slow after approval

## Accounting

As a development-stage medical device company, most spending is expensed as research and development, so trial timing can materially shift quarterly results. The company also has lease commitments and capitalized cash/investment balances to monitor, but the main accounting judgment is the timing and classification of clinical, regulatory, and commercialization-related costs before revenue begins.

- **Research and development expense recognition** — Quarterly operating loss
- **Pre-commercialization spending** — Operating expenses
- **Lease accounting** — Cash flow and liabilities

- R&D expense timing depends on clinical study progress
- Pre-commercialization costs are largely expensed as incurred
- No product revenue yet, so revenue recognition is not a current driver
- Lease commitments affect fixed obligations and cash planning
- Cash and investment balances support going-concern and liquidity analysis

---

*Last updated: 2026-04-29T05:12:17.423306+00:00*